MiniMed has commercially launched its MiniMed 780G system integrated with Abbott's Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor in Europe. These sensors are the smallest and longest-wear options from Abbott, enhancing MiniMed's diabetes management technology. The MiniMed 780G system is now available in select European markets, while the MiniMed Go system offers real-time insights and dose alerts via a mobile app, aiding users who rely on multiple daily injections. This rollout expands MiniMed's sensor portfolio and aims to improve diabetes care across Europe.
Abbott Laboratories shares have fallen from $127.12 to $90.53 due to sector-wide rotation and concerns over its $21 billion Exact Sciences acquisition. Despite this, its diabetes franchise, led by the FreeStyle Libre glucose monitor, and medical devi...
Abbott will announce its financial results for the second quarter of 2026 on July 16 before the market opens. The company will host a live webcast of the earnings call at 8 a.m. Central time, accessible via its Investor Relations website. Abbott is a...
Abbott Laboratories reported solid Q1 2026 results with revenue growth driven by its diversified healthcare segments, including a 13.2% rise in Medical Devices and a recent $21 billion acquisition of Exact Sciences to boost diagnostics. The company h...
ALZpath Inc. has signed a licensing agreement with Abbott to integrate its proprietary pTau217 antibody into an in vitro diagnostic test for Alzheimer's disease. This test will be developed for Abbott's widely used Alinity ci-series systems, enabling...
The global enteric disease testing market is projected to grow from $4.08 billion in 2025 to $5.86 billion by 2035, at a CAGR of 3.7%. Growth is fueled by rising foodborne and waterborne diseases, demand for rapid pathogen detection, and adoption of ...
